Search results
Showing 16 to 30 of 56 results for durvalumab
Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Show all sections
In development [GID-TA11503] Expected publication date: 10 September 2025
In development [GID-TA11232] Expected publication date: 28 August 2025
In development [GID-TA11289] Expected publication date: TBC
In development [GID-TA11504] Expected publication date: 24 September 2025
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Show all sections
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]
Awaiting development [GID-TA11076] Expected publication date: TBC
Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
In development [GID-NG10404] Expected publication date: TBC
Awaiting development [GID-TA11011] Expected publication date: TBC
Awaiting development [GID-TA11670] Expected publication date: TBC
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172]
Discontinued [GID-TA10394]
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]
Discontinued [GID-TA10324]
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued [GID-TA10315]
Awaiting development [GID-TA11440] Expected publication date: TBC